Get started
Author

Shakeela Wazeen Bahadur

Observed names: Bahadur SW, Shakeela Bahadur, Shakeela W Bahadur, Shakeela W. Bahadur
OpenAlex ID: A5044516340
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
2022 · C.E. Geyer, J.E. Garber, et al. · Annals of Oncology · 480
PDF
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial
2023 · Jason J. Luke, Manish R. Patel, et al. · Nature Medicine · 138
PDF
SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).
2019 · Hope S. Rugo, Seock-Ah Im, et al. · Journal of Clinical Oncology · 80
A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms.
2020 · Jason J. Luke, Manish R. Patel, et al. · Journal of Clinical Oncology · 51
Immunotherapy for the Treatment of Breast Cancer: Emerging New Data
2020 · Lida A Mina, Shannon Lim, et al. · Breast Cancer Targets and Therapy · 44
PDF
Immunotherapy for the Treatment of Breast Cancer: Emerging New Data
2020 · Mina LA, Lim S, et al. · DOAJ (DOAJ: Directory of Open Access Journals) · 29
A Phase 1, Open-Label Study of MGD013, a Bispecific DART® Molecule Binding PD-1 and LAG-3 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2020 · Jie Wang, Adam S. Asch, et al. · Blood · 25
Patient-reported outcomes (PROs) in patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, investigator’s choice standard endocrine therapy, or imlunestrant + abemaciclib: Results from the phase III EMBER-3 trial.
2025 · Giuseppe Curigliano, Joyce O'Shaughnessy, et al. · Journal of Clinical Oncology · 8
PDF
313 A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms
2020 · Manish Patel, Jason Luke, et al. · Regular and Young Investigator Award Abstracts · 6
SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) + Ctx versus trastuzumab (T) + Ctx in patients (pts) with pretreated HER2+ metastatic (met) breast cancer (MBC).
2020 · Santiago Escrivá, Seock-Ah Im, et al. · Journal of Clinical Oncology · 5
Abstract P4-01-16: High levels of RSK2 in breast cancer patients is associated with longer PFS in patients treated with PMD-026, a first in class RSK inhibitor
2023 · Judy S. Wang, Muralidhar Beeram, et al. · Cancer Research · 2
Impact of GLP1 receptor agonists on survival of breast cancer patients.
2026 · Tim Prior, Rachel E. Tripp, et al. · Journal of Clinical Oncology · 1
Abstract 2744: Automating clinical and pathological staging for breast cancer patients.
2026 · Arshad Mohammed, Umair Ayub, et al. · Cancer Research
Qualitative Interviews on the Experience of Orally vs. Intramuscularly Administered Endocrine Therapy for Advanced Breast Cancer: Patient and Healthcare Provider Perspectives
2025 · Rebecca M. Speck, Gale Harding, et al. · Oncology and Therapy
PDF
Abstract P4-03-11: Patient and health care provider perspectives on oral versus intramuscular endocrine therapy for locally advanced or metastatic breast cancer
2025 · Rebecca Speck, Spencer Schaff, et al. · Clinical Cancer Research
Abstract P2-09-16: A Phase 1b/2 study of palazestrant (OP-1250) in combination with ribociclib, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-), advanced or metastatic breast cancer
2025 · Virginia Borges, Jason A. Mouabbi, et al. · Clinical Cancer Research
Abstract PO3-29-04: Patient selection for high RSK2 expression is key for achieving improved PFS in metastatic breast cancer in the PMD-026 Phase 1/1b study
2024 · Sandra Dunn, Judy Wang, et al. · Cancer Research
Abstract PS10-24: Infusion related reactions in the phase 3 SOPHIA trial of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with pretreated HER2+ metastatic breast cancer
2021 · Javier Cortes, Fatima Cardoso, et al. · Cancer Research
Accelerated Onset of Liver Failure after Prolonged Adjuvant Tamoxifen Use in Breast Cancer Patients
2020 · Hayley M. Heers, Hayley M. Heers, et al. · Clinical Oncology and Research
Abstract P1-18-04: Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: Infusion time substudy results
2020 · William J. Gradishar, Seock-Ah Im, et al. · Cancer Research
Abstract 5385: Thymoquinone(TQ) and cisplatin(CDDP) in a non-small cell lung cancer (NSCLC) xenograft model
2010 · Syed H. Jafri, Molly Boyd, et al. · Cancer Research
Works count: 21
Citation count: 869
H-index: 8
I10-index: 7
Year
Topic
Type